Table 2 Correlation between clinicopathological features and TRIM3 expression (N = 348).
N | TRIM3 expression | |||
|---|---|---|---|---|
Negative(146) | Positive(202) | P | ||
Age | 0.533 | |||
<50 years | 20 | 6 (30.0%) | 14 (70.0%) | |
50–75 years | 207 | 90 (43.5%) | 117 (56.5%) | |
>75 years | 121 | 50 (41.3%) | 71 (58.7%) | |
Sex | 0.232 | |||
Male | 169 | 65 (38.5%) | 104 (61.5%) | |
Female | 179 | 81 (45.3%) | 98 (54.7%) | |
Tumor size | 0.604 | |||
<4 cm | 115 | 52 (45.2%) | 63 (54.8%) | |
4–6 cm | 175 | 69 (39.4%) | 106 (60.6%) | |
>6 cm | 58 | 25 (43.1%) | 33 (56.9%) | |
Tumor location | 0.403 | |||
Ascending | 85 | 34 (40.0%) | 51 (60.0%) | |
Transverse | 16 | 6 (37.5%) | 10 (62.5%) | |
Descending | 30 | 17 (56.7%) | 13 (43.3%) | |
Sigmoid | 91 | 41 (45.1%) | 50 (54.9%) | |
Rectum | 126 | 48 (38.1%) | 78 (61.9%) | |
T stage | 0.172 | |||
T1 | 19 | 9 (47.4%) | 10 (52.6%) | |
T2 | 51 | 28 (54.9%) | 23 (45.1%) | |
T3 | 198 | 80 (40.4%) | 118 (59.6%) | |
T4 | 80 | 29 (36.3%) | 51 (63.8%) | |
N stage | 0.920 | |||
N0 | 224 | 96 (42.9%) | 128 (57.1%) | |
N1 | 84 | 34 (40.5%) | 50 (59.5%) | |
N2 | 40 | 16 (40.0%) | 24 (60.0%) | |
M stage | 0.010* | |||
M0 | 324 | 142 (43.8%) | 182 (56.2%) | |
M1 | 24 | 4 (16.7%) | 20 (83.3%) | |
AJCC stage | 0.026* | |||
I | 60 | 31 (51.7%) | 29 (48.3%) | |
II | 155 | 63 (40.6%) | 92 (59.4%) | |
III | 109 | 48 (44.0%) | 61 (56.0%) | |
IV | 24 | 4 (16.7%) | 20 (83.3%) | |
Differentiation | 0.619 | |||
Well | 124 | 50 (40.3%) | 74 (59.7%) | |
Moderate | 206 | 90 (43.7%) | 116 (56.3%) | |
Poorly | 18 | 6 (33.3%) | 12 (66.7%) | |
P53 | <0.001* | |||
Negative | 136 | 79 (58.1%) | 57 (41.9%) | |
Positive | 212 | 67 (31.6%) | 145 (68.4%) | |
